- CureToday.com
- OncLive.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
Kristie L. Kahl | Authors
Articles
FDA Expands Lorlatinib Approval To Frontline Treatment of ALK-Positive Metastatic NSCLC
March 04, 2021
The agency approved the supplemental new drug application to include the first-line treatment of adult patients with metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer.
PSMA-Targeted Agent Identified Disease in Majority of Patients with Relapsed Prostate Cancer
February 12, 2021
The potential to identify occult prostate cancer and accurately characterize disease burden was observed with the novel prostate specific membrane antigen (PSMA)–targeted radiopharmaceutical for PET imaging technique.
Effective T-Cell Immunity Against Various Coronaviruses Is Possible in Stem Cell Transplant Recipients
February 09, 2021
Findings from a poster presentation at the 2021 Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR suggest the feasibility of successful vaccinations against coronaviruses in patients with hematologic malignancies following stem cell transplant.
Pembrolizumab Bests Docetaxel in 5-Year Survival in PD-L1+ Advanced NSCLC
January 30, 2021
Results from the phase 2/3 KEYNOTE-010 trial continue to favor pembrolizumab, including key survival end points.
Kevin Kalinsky, MD, MS, on Exciting Breast Cancer Treatments Coming Down the Pike
January 24, 2021
“We’re hearing about other antibody-drug conjugates, other agents in hormone receptor–positive metastatic disease, and the next generation of drugs that we’ll be using to treat our patients.”
Kevin Kalinsky, MD, MS, on Next Steps Following the Phase 3 RxPONDER Trial
January 20, 2021
Investigators aimed to evaluate additional end points from the phase 3 RxPONDER trial in women with hormone receptor–positive, HER2-negative, lymph node–positive breast cancer.
Kevin Kalinsky, MD, MS, on the RxPONDER Trial Methods
January 18, 2021
In this trial, investigators launched RxPONDER, in which 5015 patients with a recurrence score between 0 and 25 were randomized to endocrine therapy alone or chemotherapy followed by endocrine therapy.
Patients With MSI-H/dMMR mCRC Saw Improvement in PFS, HRQoL with Pembrolizumab Monotherapy
January 16, 2021
When compared with chemotherapy, patients with microsatellite-instability high/mismatch repair deficient metastatic colorectal cancer saw significant improvement in progression-free survival with the frontline use of pembrolizumab monotherapy, while demonstrating superior safety.
FDA Issues Emergency Use Authorization to Moderna COVID-19 Vaccine
December 19, 2020
The FDA issued an emergency use authorization for the second coronavirus 2019 disease vaccine, Moderna COVID-19 Vaccine, to be distributed in the U.S. for use in individuals 18 years of age and older.
FDA Approves Ponatinib To Treat Adult Patients with Resistant/Intolerant Chronic-Phase CML
December 19, 2020
The FDA approved the supplemental new drug application for ponatinib (Iclusig) to treat patients with chronic-phase chronic myeloid leukemia (CML) with resistance or intolerance to at least two prior kinase inhibitors.